Want the short version?
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
NIKI · NASDAQ · Measuring & Controlling Devices, Nec · Foreign private issuer
Niki Biosolutions (NIKI) · oqro.io/stocks/NIKI · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
No open-market purchase by an insider of Niki Biosolutions is on record in SEC filings since 2006.
No open-market sale by an insider of Niki Biosolutions (NIKI) was filed with the SEC in the last 90 days.
No trade in Niki Biosolutions (NIKI) was disclosed by a member of Congress in the last 12 months.
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
$1.57−0.11 (−6.55%)
Close of Nov 20, 2026, vs Nov 19 · end-of-day
−82.2% (−$7.26) from Jul 20, 2026 to Nov 20, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $8.83 on Jul 20, 2026 to $1.57 on Nov 20, 2026 (−82.2%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Measuring & Controlling Devices, Nec company based in Princeton, NJ. Foreign private issuer: reports on Form 20-F or 40-F.
Measuring & Controlling Devices, Nec company based in Princeton, NJ. Foreign private issuer: reports on Form 20-F or 40-F. Its directors and officers file insider-trading forms (Form 4) only since 18 March 2026.
Last 12 months
Not enough history
Market value
–
Short interest: 1,717 shares sold short, −70.1% vs the previous count, 1.0 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Nothing reported yet
New filings show up here as soon as they are processed.
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Said its annual or quarterly report would be late
NT 10-Q on sec.govTop officer leaving
“On October 9, 2026, the Board of Directors (the “Board”) of Niki BioSolutions, Inc., a Delaware corporation (the “Company”), appointed Thomas Freeburg as the Chief Financial Officer, to serve at the discretion of the Board, for a period of two years, commencing as of September 1, 2026, unless terminated sooner by either party.”
8-K on sec.govFrom the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
Against the S&P 500 over the year
Since Jul 20, 2026, NIKI is down 82.2% and the index fund is down 7.0%: 75 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much NIKI moves
End-of-day prices. These figures describe the past year and say nothing about what comes next.
No Schedule 13D or 13G filing on NIKI over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Contracts, lobbying and filings
Company reports, price and press
Things to keep in mind
Records
Every annual report has a section where the company's managers explain the year's results (Item 5, Operating and financial review). In this report it runs to about 8,000 words.
We are a clinical stage biopharmaceutical company dedicated to the discovery, development and commercialization of therapeutic assets to treat diseases with unmet medical needs, particularly in oncology (including orphan oncology indications) and infectious diseases. Based on our evaluation of preliminary data and our consideration of a number of factors including substantial unmet needs, benefits over existing therapies, potential market size, competition in market, the Company decides how to prioritize its resources among projects. Overall, our rationale for selecting Lead Projects is not based on any mechanical formula or rigid selection criteria, but instead focused on a combination of the factors and individual attributes of the Lead Projects themselves.
And 21 more headings in the filing.
Source: SEC EDGAR, Form 20-F filed Mar 27, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Off-exchange trading: 32.6% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (4.9% on ATS, 27.7% with other brokers), below its 13-week average of 45.8%. Weeks of Sep 21 to Oct 16, 2026.
Largest ATS: UBS ATS (33.9%), SIGMA X2 (14.9%), IBKR ATS (14.6%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.
Latest annual report filed Mar 27, 2026, compared with the one filed Apr 30, 2025. Read the filing
And 6 more headings in the filing.
Source: SEC EDGAR, Form 20-F filed Mar 27, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.